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ABSTRACT 
 
Background: Pulmonary TB is one of the most important health problems in Indonesia. The 
number of pulmonary TB patients ranked second after India. Vitamin D has a complex effect in the 
immune system. One of the effects of vitamin D is to stimulate the production of Cathelicidin which 
increases macrophage phagocytosis. This study aimed to analyze the effect of complementary 
vitamin D on sputum conversion in pulmonary tuberculosis patients.  
Subjects and Method: This study was a randomized controlled trial conducted at several health 
centers in Deli Serdang, North Sumatera, from November 2015 to June 2016. A total sample of 80 
patients with positive acid-resistant bacilli (BTA) was selected for this study by consecutive 
sampling. The sample was allocated randomly into two groups: (1) TB drug group + 2.5 mg vitamin 
D; (2) TB drug group + placebo. The dependent variable was sputum conversion. The independent 
variable was complementary vitamin D. Pre and post vitamin D levels were examined by ELISA 
technique. Sputum conversion was examined by TB laboratory worker at the health center where 
patients received TB drug treatment. Difference in percent of sputum conversion between the two 
groups was tested by chi-square test. Difference in mean of sputum conversion time between the 
two groups was tested by t-test. 
Results: The mean serum vitamin D level in the intervention group (62.05±22.08) was higher 
than the control group (28.56±7.48) after the intervention, and it was statistically significant 
(p<0.001). After 56 days, all subjects in the vitamin D group experienced sputum conversion 
(100%) with a median sputum conversion time of 28 days, whereas 90% of subjects in the placebo 
group experienced sputum conversion with a median sputum conversion time of 48 days (p= 
0.002).  
Conclusion: Adding vitamin D to anti-TB drug treatment effectively improves and accelerates 
sputum conversion of patients with tuberculosis acid-fast bacilli smear positive. 
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BACKGROUND 
Tuberculosis (TB) is a major public health 
threat. According to WHO, Indonesia 
ranked second of TB burden worldwide 
(WHO, 2014). Genetic factor is a factor that 
may explain why some people are more 
resistant to Mycobacterium tuberculosis 
infection than others. Environmental and 
genetic factors determine the development 
of clinical disease in people infected with 
M. tuberculosis (Rosenberg et al., 2007). 
Vitamin is an essential organic 
substance for a human body. Vitamin D and 
its metabolites are essential in the body's 
physiological processes, such as bone 
control and calcium homeostasis (Selvaraj, 
2011). 
Vitamin D especially vitamin D 
metabolites (1.25 (OH) 2D3) stimulates the 
production of anti-bacterial peptides such 
as Cathelicidin and Defensin (Rashedi et al, 
2015; Dini and Baianchi, 2012). Previous 
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study has shown the important role of 
vitamin D in regulating the immune system 
through its binding with Vitamin D 
Receptor (VDR) (Junaid et al, 2016; Mar-
tineau et al, 2012; Selvaraj et al, 2008). 
TB patients had low vitamin D level. 
Several studies have found that vitamin D 
level indicates the body's defense ability 
against M. tuberculosis infection. It is 
known that vitamin D activated metabolite 
1.25-dihydroxy vitamin D3 (1.25D3) can 
enhance natural immune regulation against 
Mycobacterium tuberculosis (Martineau et 
al, 2011, Haussler et al, 2013; Simon et al, 
2013; Coussens et al, 2012). 
The effect of vitamin D on TB therapy 
has been extensively studied in Cipto 
Mangunkusumo Hospital, Jakarta, in 
Malang, and Wonosobo. The study showed 
that vitamin D therapy can enhance sputum 
conversion (Nursyam, 2006; Siswanto, 
2009; Pratiwi, 2013). 
This study aimed to determine the 
effect of vitamin D on smear sputum 
conversion in pulmonary tuberculosis 
patients in Deli Serdang District, North 
Sumatera.  
 
SUBJECTS AND METHOD 
1. Study design 
This was a randomized controlled trial 
(RCT) conducted at community health 
centers in Deli Serdang District, North 
Sumatera, from November 2015 to June 
2016.  
2. Population and sample 
A total sample of 80 Tuberculosis patients 
was selected for this study. Critical 
inclusion of study subjects was newly 
diagnosed lung tuberculosis, positive 
sputum, minimum age 18 years, and BMI 
≥18.5. Exclusion criteria were HIV positive, 
taking immunopresive drugs, kidney failure 
and diabetes mellitus.  
A total sample of 80 patients with 
positive acid-resistant bacilli (BTA) was 
selected for this study by consecutive 
sampling. The sample was allocated ran-
domly into two groups: (1) TB drug group + 
2.5 mg vitamin D (intervention group); (2) 
TB drug group + placebo (control group). 
The intervention group received four doses 
of 2.5 mg vitamin D3 (Bio-tech pharma-
ceutical, US) every two weeks (0, 14, 28, 
and 42 days) (Martineau et al, 2011). 
3. Study Variables 
The dependent variables were serum 
vitamin D level, percent and duration of 
sputum conversion. The independent varia-
ble was adding vitamin D on TB drug 
therapy. 
Vitamin D status was categorized as 
deficient (<20 ng/ml), insufficiency (20-30 
ng/ml), and optimal (≥30 ng/ml) (Mar-
tineau et al, 2011; Junaid et al, 2016; Jo-
lliffe et al, 2015). 
4. Study Procedure 
Before the intervention, blood samples 
were taken from all patients to check pre-
vitamin D levels with ELISA. Vitamin D and 
placebo were administered in 4 doses of 2.5 
mg (bio-tech Pharmacal, US) with the time 
of administration of 0, 14, 28, and 42 days. 
TB drug with or without vitamin D was 
given every 2 weeks. Patients were followed 
for two months and examined for sputum 
conversion every two weeks (14 days, 28 
days, 42 days and 56 days). Sputum 
specimens were examined to determine the 
presence of Acid-Fast Bacilli (AFB) 
(Martineau et al., 201; Nursyam et al., 
2006; Babb et al., 2007). 
Sputum conversion checks were per-
formed by medical laboratory technicians at 
the community health centers. Vitamin D 
level was measured using ELISA at the 
Integrated Laboratory Unit, Faculty of 
Medicine, University of North Sumatra, 
Medan. 
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5. Data analysis 
Difference in percent of sputum conversion 
between the two groups was tested by chi-
square test. Difference in mean of sputum 
conversion time between the two groups 
was tested by t-test. 
6. Research ethics approval 
This study complied with the ethical 
standard set by the Declaration of the 
World Medical Association of Helsinki. It 
was approved by the Institutional Review 
Board of the Faculty of Medicine, Univer-
sity of North Sumatra, Ministry of Edu-
cation and Culture of the Republic of 
Indonesia. All study subjects have provided 
written informed consent.  
 
RESULTS 
Table 1 described the characteristic of the 
study subjects. Anti-tuberculosis drugs 
were given in accordance with the DOTS 
program category I: 2RHZE / 4RH. 
Table 1 showed that the mean 
difference of serum Vitamin D level before 
intervention was comparable between the 
intervention (31.78±9.45) and the control 
group (26.85±8.22), and it was statistically 
non-significant (p= 0.290). It means that 
randomization had successfully allocated the 
baseline serum vitamin D level evenly 
between the two groups. 
Table 1 also showed that the mean 
serum vitamin D level in the intervention 
group (62.05±22.08) was higher than the 
control group (28.56±7.48) after the inter-
vention, and it was statistically significant 
(p<0.001). It means that the administration 
of vitamin D effectively increased the serum 
vitamin D level in the intervention group. 
Table 1. Characteristic of the study subjects 
Variables Vitamin D Placebo p 
Sex    
- Male 26 (65%) 27 (68%) 0.810 
- Female 14 (35%) 13 (32%)  
Occupation    
- Employed 23 (58%) 25 (63%)  
- Unemployed 12 (30%) 13 (32%) 0.490 
- Student 5 (12%) 2 (5%)  
Baseline sputum smear    
- +1 10-99 AFB/100 fields 21 (53%) 8 (20%)  
- +2 1-10   AFB/50 fields 9 (22%) 19 (48%) 0.007 
- +3  >10   AFB/20 fields 10 (25%) 13 (32%)  
Vitamin D Status    
- Deficient 6 (15%) 9 (22%)  
- Insufficient 11 (27%) 15 (38%) 0.290 
- Optimal 
Vitamin D Pre (ng/ml) 
Vitamin D Post (ng/ml) 
23 (58%) 
31.78±9.45 
62.05±22.08 
16 (40%) 
26.85±8.22 
28.56±7.48 
 
0.290 
<0.001 
 
Figure 1 showed that after 56 days, all 
subjects in the vitamin D group experienced 
a conversion (100%) with a median sputum 
conversion time of 28 days. 90% of subjects 
in the placebo group experienced a 
conversion with a median sputum 
conversion time of 48 days (p= 0.002). 
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Figure 1. Sputum smear conversion time and number of  
positive Acid-Fast Bacilli (AFB) in the intervention and control group 
 
DISCUSSION 
This study indicated that the vitamin D 
serum level in the vitamin D group was 
higher than that in the control group. This 
increase in vitamin D level came from the 
high dose of vitamin D provided and from 
food consumed. Vitamin D has a specific 
role in the natural immune system as an 
agent that fights against infection. 
Specifically, the active metabolite of 
vitamin D will stimulate macrophages 
through Cathelicidin protein in M. 
tuberculosis phagocytosis.  
The present study also found that the 
percent of sputum conversion was higher in 
the vitamin D group than in that control 
group. The sputum conversion time was 
also shorter in the vitamin D group than in 
the control group. These findings indicate 
that adding vitamin D to anti-TB drug 
treatment effectively improves and 
accelerates sputum conversion of patients 
with tuberculosis acid-fast bacilli smear 
positive. These findings are consistent with 
previous studies in Indonesia and in England 
(Coussens et al., 2012; Nursyam et al., 
2009; Martineau et al., 2016). 
There were 4 subjects who did not 
undergo conversion in the control group. 
The initial AFB status of all four subjects 
was +3 that took longer for conversion. One 
possibility of this longer conversion is due 
to MDR TB. Parikh et al. (2012) state that 
patients with higher number of acid-
resistant TB bacilli (+3) has a higher risk of 
developing a drug-resistant mutant than 
those with lower number of acid-resistant 
bacilli (+2 and +1). 
This study showed that comple-
mentary vitamin D effectively increase the 
sputum conversion and shorten the sputum 
conversion time. Therefore, provision of 
vitamin D in patients with TB is highly 
recommended as one way to break the 
chain of transmission of infectious germs 
TB. Supplementation of vitamin D can 
improve the patient's immune system by 
encouraging the production of cataracts 
that play a role in combating tuberculosis 
germs (Martineau et al, 2011; Chen et al, 
2013; Lee & Song, 2015). 
Micronutrients as additional immu-
notherapy are potentially developed and 
become a medical concern because scien-
tific evidence of anti-microbacterial activity 
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specific to vitamin D3 in macrophages has 
been overwhelming. This needs to be 
considered as an additional therapy in TB 
cases (Nursyam et al, 2009, Martineau et 
al, 2011; Coussens et al, 2012). 
This study concludes that adding 
vitamin D to anti-TB drug treatment effect-
tively improves and accelerates sputum 
conversion of patients with tuberculosis 
acid-fast bacilli smear positive. It is 
suggested that supplementary Vitamin D be 
added to anti-TB drug treatment to 
enhance its effectiveness. 
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